Article
An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion
4 Nov 2018
Abstract excerpt
Despite breakthroughs in immune checkpoint inhibitor (ICI) immunotherapy, not all human cancers respond to ICI immunotherapy and a large fraction of patients with the responsive types of cancers do not respond to current ICI immunotherapy. This clinical conundrum suggests that additional immune checkpoints exist. We report here that interferon regulatory factor 8 (IRF8) deficiency led to impairment of cytotoxic T...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
